The prevalence is unknown but it accounts for approximately 3% of gastrointestinal tumors and 10-15% of all hepatobiliary malignancies[1].
In the United States, an estimated 20,000 new cases of liver and biliary tract cancer are diagnosed annually. Biliary tract cancer is the second most common primary hepatobiliary cancer, after hepatocellular cancer. Approximately 7,500 new cases of biliary tract cancer are diagnosed each year; about 5,000 of these are gallbladder cancer, and between 2,000 and 3,000 are bile duct cancers[2].
Trial Description
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107
Trial Center
Phoenix, AZMayo Clinic
Phoenix, Arizona, United States, 85054
Justin Weber
480-342-6029
Weber.Justin@mayo.edu
San Francisco, CAUniversity of California
San Francisco, California, United States, 94143
Pranay Chaurasia
415-353-8449
Pranay.Chaurasia@ucsf.edu
Boston, MAMassachusetts General Hospital
Boston, Massachusetts, United States, 02114
Amy Gisondi
AGISONDI@mgh.harvard.edu
Boston, MABeth-Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Justin Sun
617-975-7463
jsun7@bidmc.harvard.edu
Boston, MADana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Alexandra Bird
617-632-5575
Alexandra_Bird@DFCI.HARVARD.EDU
Seattle, WAUnited States, Washington University of Washington, Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Camille Biggins
206-606-1646
cbiggins@seattlecca.org
Taichung, TWChina Medical University Hospital
Taichung, Taiwan, 404
Yu-Ting Ho
04-22052121 ext 5057
blessyou1982@gmail.com
Tainan, TWNational Cheng Kung University Hospital
Tainan, Taiwan, 48
Ray-Fan Su
0910-876172
srf106@gmail.com
Taipei, TWNational Taiwan University Hospital
Taipei, Taiwan, 100
Citations
1. Bile duct cancer. NIH. Available at
2. Pancreatic & Biliary Cancer. NIH. Available at
Details about AltruBio Clinical Trial can be found at ClinicalTrials.gov